Iovance Biotherapeutics Inc (IOVA) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Iovance Biotherapeutics Inc (IOVA) has a cash flow conversion efficiency ratio of -0.112x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-78.70 Million) by net assets ($702.29 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See IOVA equity to assets ratio to measure how much of total assets are equity-financed.
Iovance Biotherapeutics Inc - Cash Flow Conversion Efficiency Trend (2008–2024)
This chart illustrates how Iovance Biotherapeutics Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check Iovance Biotherapeutics Inc (IOVA) cash earnings ratio to evaluate the quality of earnings relative to operating cash generation.
Iovance Biotherapeutics Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Iovance Biotherapeutics Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Hangzhou Cogeneration Group Co Ltd
SHG:605011
|
0.006x |
|
Tiangong International Company Limited
F:34T1
|
0.010x |
|
E2open Parent Holdings Inc
NYSE:ETWO
|
0.046x |
|
Orezone Gold Corp
TO:ORE
|
0.301x |
|
alstria office REIT-AG
XETRA:AOX
|
-0.004x |
|
Fnac Darty SA
PA:FNAC
|
-0.386x |
|
Pearl Global Industries Limited
NSE:PGIL
|
0.190x |
|
Hengkang Medical Group Co Ltd
SHE:002219
|
0.005x |
Annual Cash Flow Conversion Efficiency for Iovance Biotherapeutics Inc (2008–2024)
The table below shows the annual cash flow conversion efficiency of Iovance Biotherapeutics Inc from 2008 to 2024. For the full company profile with market capitalisation and key ratios, see Iovance Biotherapeutics Inc market capitalisation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $710.40 Million | $-352.98 Million | -0.497x | +19.72% |
| 2023-12-31 | $584.61 Million | $-361.82 Million | -0.619x | -5.63% |
| 2022-12-31 | $499.64 Million | $-292.76 Million | -0.586x | -59.80% |
| 2021-12-31 | $621.66 Million | $-227.94 Million | -0.367x | -17.35% |
| 2020-12-31 | $656.50 Million | $-205.13 Million | -0.312x | +41.21% |
| 2019-12-31 | $298.97 Million | $-158.89 Million | -0.531x | -144.70% |
| 2018-12-31 | $466.19 Million | $-101.25 Million | -0.217x | +59.86% |
| 2017-12-31 | $145.48 Million | $-78.71 Million | -0.541x | -176.44% |
| 2016-12-31 | $166.92 Million | $-32.67 Million | -0.196x | -10.76% |
| 2015-12-31 | $104.02 Million | $-18.38 Million | -0.177x | +8.21% |
| 2014-12-31 | $44.85 Million | $-8.63 Million | -0.193x | +7.46% |
| 2013-12-31 | $17.60 Million | $-3.66 Million | -0.208x | -205.06% |
| 2012-12-31 | $-11.32 Million | $-2.24 Million | 0.198x | -59.11% |
| 2011-12-31 | $-12.78 Million | $-6.19 Million | 0.484x | +149.77% |
| 2010-12-31 | $638.09K | $-620.80K | -0.973x | -190.83% |
| 2009-12-31 | $-13.49K | $-14.45K | 1.071x | +104.27% |
| 2008-12-31 | $2.28K | $-57.30K | -25.089x | -- |
About Iovance Biotherapeutics Inc
Iovance Biotherapeutics, Inc., a commercial-stage biopharmaceutical company, develops and commercializes cell therapies using autologous tumor infiltrating lymphocyte for the treatment of metastatic melanoma and other solid tumor cancers in the United States. The company offers Amtagvi, a tumor-derived autologous T cell immunotherapy used to treat adult patients with unresectable or metastatic me… Read more